A humanized anti-TROP2 IgG1 antibody-drug conjugate that, after binding TROP2 on tumor cells and internalization, releases a membrane-permeable topoisomerase I inhibitor (DXd) via a cleavable linker to induce DNA damage, replication stress, and tumor cell death with a bystander effect.
Humanized anti-TROP2 IgG1 antibody-drug conjugate; after binding TROP2 and internalization, a cleavable linker releases the DXd topoisomerase I inhibitor payload, inducing DNA damage and replication stress to kill tumor cells, with a membrane-permeable bystander effect.
NO
INDIRECT
Dato-DXd binds TROP2 on cells, is internalized, and releases a DXd topoisomerase I inhibitor that causes DNA damage. Topoisomerase I is the intracellular enzyme targeted by the payload, not the cell-surface antigen; cells are killed only if TROP2-positive (or via bystander effect), not because they express topoisomerase I.
A bispecific antibody immunotherapy evaluated in a Phase 1 dose-escalation/expansion study for relapsed/refractory B-cell non-Hodgkin lymphoma. It is designed to bind two targets and redirect immune effector activity to malignant B cells. Dosed across 0.3-500 mg for up to 12 months. Specific antigens and effector mechanisms are not disclosed.
Bispecific antibody that links T cells to malignant B cells—binding CD3 on T cells and a B‑cell antigen—to form an immunologic synapse and trigger T‑cell–mediated cytotoxic killing; specific targets are not disclosed.
NO
INDIRECT
The bispecific engages CD3 on T cells to activate them and form an immunologic synapse; T cells kill B‑cell targets via perforin/granzyme release. CD3+ T cells themselves are not the killed cells.
A bispecific antibody immunotherapy evaluated in a Phase 1 dose-escalation/expansion study for relapsed/refractory B-cell non-Hodgkin lymphoma. It is designed to bind two targets and redirect immune effector activity to malignant B cells. Dosed across 0.3-500 mg for up to 12 months. Specific antigens and effector mechanisms are not disclosed.
Bispecific antibody that links T cells to malignant B cells—binding CD3 on T cells and a B‑cell antigen—to form an immunologic synapse and trigger T‑cell–mediated cytotoxic killing; specific targets are not disclosed.
YES
DIRECT
The bispecific antibody bridges CD3 on T cells to the B‑cell antigen on target cells, forming an immunologic synapse and triggering T‑cell–mediated cytotoxicity (perforin/granzyme and Fas–FasL apoptosis).
TROP2-directed antibody-drug conjugate; a humanized anti-TROP2 monoclonal antibody that is internalized upon binding and releases a topoisomerase I inhibitor payload to induce DNA damage and cell death.
Humanized anti-TROP2 monoclonal antibody binds TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage and tumor cell death.
YES
DIRECT
The anti-TROP2 antibody–drug conjugate binds TROP2, is internalized, and releases a topoisomerase I inhibitor payload that induces DNA damage and apoptosis in the target cell.
Autologous, gene-modified CAR T cells engineered to express an anti-CD30 chimeric antigen receptor and CCR4 to enhance trafficking to the Hodgkin lymphoma microenvironment; CAR engagement of CD30 triggers T-cell activation and cytotoxicity.
Autologous T cells are gene-modified to express an anti‑CD30 chimeric antigen receptor and the chemokine receptor CCR4. CAR binding to CD30 on malignant cells triggers T‑cell activation, cytokine release, proliferation, and targeted cytotoxicity, while CCR4 enhances trafficking to the Hodgkin lymphoma microenvironment via CCL17/CCL22 gradients.
NO
INDIRECT
CCL17 serves as a chemotactic ligand for CCR4 on the CAR T cells, aiding trafficking. Killing occurs only when the CAR engages CD30 on target cells, triggering T‑cell cytotoxicity (perforin/granzyme), not via CCL17.